FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 361:1717-1720 October 29, 2009 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The 2009 federal stimulus package included $1.1 billion to support comparative-effectiveness research about medical treatments. No money has been allocated — and relatively little would be needed — to disseminate existing but practically inaccessible information about the benefits and harms of prescription drugs. Much critical information that the Food and Drug Administration (FDA) has at the time of approval may fail to make its way into the drug label and relevant journal articles.

The most direct way that the FDA communicates the prescribing information that clinicians need is through the drug label. Labels, the package inserts that come with medications, . . . [Full Text of this Article]

Source Information

From the Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH; and the VA Outcomes Group, VA Medical Center, White River Junction, VT.

This article (10.1056/NEJMp0907708) was published on October 21, 2009, at NEJM.org.

This article has been cited by other articles:

• (2009). All you need to read in the other general journals. BMJ 339: b4389-b4389 [Full Text]